ISIS Pharm., Inc
Article Abstract:
Isis Pharmaceuticals is engaged in the discovery and development of antisense drugs. A comparative analysis of the company sales and financial details of from 1991 to 2003 are illustrated. Projections of the annual total returns, revenues and the assets position of the company for the period 2007-09 are made using value line estimates.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Vertex Pharmaceuticals Inc
Article Abstract:
Vertex Pharmaceuticals Inc. is selling its biochemical and cellular assay capabilities and commercial portfolio of properties to Invitrogen to concentrate on discovery and development of drugs. Shares have risk but also appreciation potential out to 2006-2008.
Publication Name: The Value Line Investment Survey (Part 3 - Ratings & Reports)
Subject: Business, general
ISSN: 0042-2401
Year: 2003
User Contributions:
Comment about this article or add new information about this topic: